Research projects from CRIG teams funded by 'Kom op tegen Kanker' (2025 grants)

CRIG

Kom op tegen Kanker invests in promising cancer research projects and innovative care initiatives, which increase survival rates and improve the quality of life of (ex-)patients. Read more (in Dutch) on the website of Kom op tegen Kanker.

Congratulations to all cancer researchers in Ghent (CRIG) that were awarded in 2025, for more than 2.6 million EUR in total!
 

Biomedical - translational research projects

  • Prof. Olivier De Wever - 'A study of the safety, toxicity, and efficacy of Pelophen B, a non-taxoid microtubule-stabilizing agent' (588 000 EUR)
  • Prof. Steven Goossens - 'Asparagine deprivation as a therapy for ASNS-low ovarian cancer patients using a mammalian L-asparaginase with fewer toxic side effects' (594 500 EUR)
     

Prevention research projects

  • Maité Verloigne - 'Clear Air Collaborative: a co-creation kit to develop and implement actions to prevent (e-)cigarette use among adolescents following vocational education' (510 955 EUR)
     

Psychosocial research projects

  • Dr. Renée Bultijnck - 'Development and pilot testing of an interactive and educational group session series on "intimacy and sexuality" ' (205 234 EUR)
  • Prof. Piet Ost  - 'PK-PEP: Implementation of an online home-based health promotion patient empowerment program for men with prostate cancer' (338 180 EUR)
     

Emmanuel Van der Schueren grants (starting & finishing grants for doctoral researchers)

  • (promotor: Prof. Steven Goossens) - 'Targeting amino acid metabolic dependencies in metastatic breast cancer' (80 000 EUR) 
  • (promotor: Prof. Phillip Blondeel) - 'The development of a natural, autologous and vascularized breast implant for breast reconstruction' (28 078 EUR) 
  • (promotor: Prof. Wim Ceelen) - 'Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis of Gastrointestinal Cancer: A Phase I Study' (85 000 EUR) 
  • (promotor: Prof. Kaat Durinck) - 'Preclinical in vivo investigation of new generation RRM2 and CHK1 inhibitor combination treatment in neuroblastoma' (60 400 EUR) 
  • (promotor: Prof. Lieve Brochez) - 'Artificial Intelligence for early detection of skin cancer' (85 000 EUR) 
  • (promotor: Prof. Nick Verhaeghe) - 'Measuring the health and economic impact of skin cancer to optimize skin cancer care in Belgium' (85 000 EUR)